Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (51-60 of 162) with videos related to

Pageof 17
Sort By:
Clinical Chemistry|April 27, 2004
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to ImatinibSimona Soverini, Giovanni Martinelli, Marilina Amabile, et al.
Plos One|December 17, 2013
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemiaElisa Leo, Manuela Mancini, Michela Aluigi, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2009
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?Massimo Breccia, Anna Maria Frustaci, Laura Cannella, et al.
Leukemia|March 26, 2022
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemiaMichele Baccarani, Francesca Bonifazi, Simona Soverini, et al.
Molecular Cancer Therapeutics|September 16, 2008
Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulationStefano Monteghirfo, Francesca Tosetti, Claudia Ambrosini, et al.
Haematologica|July 18, 2009
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failureFrancesca Palandri, Fausto Castagnetti, Simona Soverini, et al.
Cancers|February 15, 2022
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast CellsManuela Mancini, Cecilia Monaldi, Sara De Santis, et al.
European Journal of Haematology|April 20, 2004
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemiaPier Paolo Piccaluga, Michele Malagola, Michela Rondoni, et al.
Haematologica|October 9, 2002
Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosisSimona Soverini, Carolina Terragna, Nicoletta Testoni, et al.
BMC Cancer|August 7, 2017
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case reportCaterina De Benedittis, Cristina Papayannidis, Claudia Venturi, et al.
Pageof 17

Showing results (51-60 of 162) with videos related to

Sort By:
Pageof 17
Clinical Chemistry|April 27, 2004
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to ImatinibSimona Soverini, Giovanni Martinelli, Marilina Amabile, et al.
Plos One|December 17, 2013
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemiaElisa Leo, Manuela Mancini, Michela Aluigi, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2009
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?Massimo Breccia, Anna Maria Frustaci, Laura Cannella, et al.
Leukemia|March 26, 2022
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemiaMichele Baccarani, Francesca Bonifazi, Simona Soverini, et al.
Molecular Cancer Therapeutics|September 16, 2008
Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulationStefano Monteghirfo, Francesca Tosetti, Claudia Ambrosini, et al.
Haematologica|July 18, 2009
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failureFrancesca Palandri, Fausto Castagnetti, Simona Soverini, et al.
Cancers|February 15, 2022
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast CellsManuela Mancini, Cecilia Monaldi, Sara De Santis, et al.
European Journal of Haematology|April 20, 2004
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemiaPier Paolo Piccaluga, Michele Malagola, Michela Rondoni, et al.
Haematologica|October 9, 2002
Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosisSimona Soverini, Carolina Terragna, Nicoletta Testoni, et al.
BMC Cancer|August 7, 2017
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case reportCaterina De Benedittis, Cristina Papayannidis, Claudia Venturi, et al.
Pageof 17